LSE company dividends information has been updated. You can find this is in the menu on any Quote page. ADVFN team.


Rtw Venture Fund Limited

0.005 (0.41%)
Share Name Share Symbol Market Type Share ISIN Share Description
Rtw Venture Fund Limited LSE:RTW London Ordinary Share GG00BKTRRM22 ORD NPV
  Price Change % Change Share Price Shares Traded Last Trade
  0.005 0.41% 1.23 14,432 16:35:12
Bid Price Offer Price High Price Low Price Open Price
1.20 1.26
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Trust,ex Ed,religious,charty 2.17 -5.29 -0.03 - 261.24
Last Trade Time Trade Type Trade Size Trade Price Currency
11:00:21 O 87 1.224 USD

Rtw Venture (RTW) Latest News

Rtw Venture (RTW) Discussions and Chat

Rtw Venture Forums and Chat

Date Time Title Posts
09/5/202322:48::: RTW VENTURE FUND :::8

Add a New Thread

Rtw Venture (RTW) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type

Rtw Venture (RTW) Top Chat Posts

Top Posts
Posted at 09/5/2023 22:48 by rambutan2
RTW Venture Fund Limited (the "Company"), a London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors, is pleased to note the announcement by one of its portfolio companies, Acelyrin, Inc. ("Acelyrin") regarding its pricing of an upsized $540 million initial public offering ("IPO") and admission to trade on Nasdaq Global Market under ticker "SLRN".

Acelyrin is a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative medicines in immunology. Its lead product candidate, Izokibep, is a small protein therapeutic designed to inhibit interleukin-17A (IL-17A) with high potency and the potential for robust tissue penetration due to its small molecular size, about one-tenth the size of a monoclonal antibody. Izokibep is in late-stage clinical development across multiple indications including hidradenitis suppurative, psoriatic arthritis, uveitis and axial spondylarthritis.

Prior to IPO, the Company, together with other funds managed by RTW Investments, LP (the "Investment Manager"), participated in Acelyrin's $250 million Series B financing round in November 2021.

Acelyrin's IPO raised $540 million by offering 30 million shares at $18.00 per share. On the first day of trading, Acelyrin's share price traded up by 30.55% to close at $23.50 per share.

Roderick Wong, MD, Managing Partner and Chief Investment Officer at the Investment Manager, said:
"We are excited about Acelyrin's successful debut on the public markets, the third from our portfolio this year in an otherwise challenging capital market, and we look forward to supporting the company in its efforts to develop new treatments for inflammatory conditions. "


Posted at 06/5/2023 04:08 by rambutan2
Good interview with another top bio crossover investor, Dr. Chen Yu, Founder & Managing Partner at TCGX. Many similarities to RTW. And like them, he's currently pretty bullish.


Posted at 27/4/2023 16:43 by rambutan2
A worthwhile listen:

Rod Wong is the founder and Managing Partner of RTW Investments, a life sciences-focused investment and innovation firm of 80 professionals that manages $6 billion in assets.

I had a chance to drop by Rod’s office in NYC and discuss his background, case for life sciences, investment and business approach, investment process across sourcing ideas, research, probability assessment of binary outcomes, portfolio construction, competition, and outlook.


Posted at 17/4/2023 15:30 by rambutan2
And back up we go, thanks to this timely takeover!

RTW Venture Fund Limited (the "Company" or "RTW Venture Fund"), a London Stock Exchange-listed investment fund focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by Prometheus Biosciences, Inc. (NASDAQ: RXDX) ("Prometheus"), that it has entered into a definitive agreement under which Merck, through a subsidiary, has agreed to acquire Prometheus for $200.00 per share in cash for a total equity value of approximately $10.8 billion, a c. 75% premium to the prior closing price. The acquisition is subject to Prometheus Biosciences shareholder approval and is expected to close in the third quarter of 2023.

Prometheus is the largest holding in RTW Venture Fund's portfolio, representing c. 14.8% of NAV at 31 March 2023. As such, the Company expects that this will translate into a material accretion to the NAV.

Posted at 11/4/2023 21:35 by rambutan2
Just as well for me I only took a small position as the price rapidly fell from $1.20 to $1, at which price I've been adding. On a discount of 35% to last reported nav, and from what I can see, no obvious disasters in the portfolio, RTW currently appears to be suffering from some very keen selling. Imho, it won't be down here for long.

Here's a run through the fund with the manager from Jan:


Posted at 31/3/2023 22:36 by rambutan2
AR out today. I recently took a small position in what I think is the pick of the Bio trusts:

Roderick Wong, MD, Managing Partner and Chief Investment Officer of RTW Investments, LP (the "Investment Manager") commented:
"We are pleased to report another robust set of results for the RTW Venture Fund in 2022. We find ourselves in unprecedented market conditions, having witnessed the second consecutive year of a bear market in the biotech sector.

"Given these challenging times, we are happy to report that the Group has once again significantly outperformed the Russell 200 Biotech Index (the most appropriate performance comparator), with a -10.2% NAV return for the period, against a -31.3% return for the Index.

"The Group's successful strategy of selecting high-quality transformative assets with significant growth potential could be seen in our core portfolio, which held up well, contributing +0.2% to NAV during 2022. Whilst only a modest return, it compares favourably to the weak performance of the Group's sector indices.

"Due to the adverse market conditions, 2022 saw just two of our portfolio companies IPO. RTW added three new companies to the portfolio and disposed of seven. Disposals crystalised a +1.6% contribution to NAV for the year with the proceeds being redeployed into other public opportunities.

"Most importantly, we continue to see public market valuations at significant discounts to historic levels, providing extremely compelling investment opportunities, with many of potential best-in-class therapeutics trading at notable lows compared to their long-term benchmarks. Our resources and expertise place us in an excellent position to capitalise on these trends and achieve significant value for shareholders over the medium- to long-term."


Research: hTTps://

Reported manager positions: hTtps://


Posted at 29/10/2019 06:19 by jonwig
Issue Price = Opening NAV = $1.0397. 161,544,695 shares in issue.

Rtw Venture share price data is direct from the London Stock Exchange
Your Recent History
Rtw Ventur..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230602 16:26:35